Invivotek, a Genesis Biotechnology Group company and leading in vivo pharmacology contract research organization, completed its Genesis Solar Farm adjacent to its newly expanded preclinical research facility in Hamilton, New Jersey.
The solar farm provides a cleaner, renewable energy source to reduce costs and lessen the CRO facility's impact on the environment. Completion of the Genesis Solar Farm follows Invivotek's recent expansion from a 19,712 square foot to a 26,453 square foot facility. The expansion translates to a 100% increase in capacity.
Invivotek noted it joins many other pharmaceutical and biotech companies worldwide who have made a commitment to invest in solar power. This project advances the efforts of GBG to reduce high energy costs associated with research and improve their environmental profile.
"Construction of the solar farm at Invivotek's research facility will not only reduce its carbon footprint, but it's also a good business decision," said Dr. Eli Mordechai, CEO of Genesis Biotechnology Group. "We are committed to good stewardship, not only of our clients' projects, but also of our community and the environment."
The solar system is expected to produce over 1.2 million kilowatt hours per year. The savings to Invivotek will be in excess of $230,000 per year (enough to power 127 households for one year) and will provide over 60% of Invivotek's energy needs.